Extends drug inflation rebates to commercial market, potentially lowering costs for many Americans.
This bill would make drug companies pay rebates if they raise prices too fast for drugs sold in the commercial market, not just for Medicare. It would also use an earlier year (2016 instead of 2021) to calculate these price increases. This could mean lower drug costs for millions of Americans who buy their prescriptions outside of Medicare.
Today, drug companies pay inflation rebates mainly for drugs covered by Medicare Part B and Part D, using a base year of 2021. If this bill passes, these inflation rebates would also apply to drugs sold in the commercial market, and the base year for calculations would shift to 2016. This change would mean more drugs are subject to inflation rebates, potentially leading to lower costs for people with private insurance.
S 1186 · 119th Congress · March 27, 2025 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers